Wharton's jelly derived mesenchymal stem cell therapy (Instituto de Medicina Regenerativa)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameWharton's jelly derived mesenchymal stem cell therapy (Instituto de Medicina Regenerativa)

Drug Alias NameUCMSC therapy (Instituto de Medicina Regenerativa)

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Umbilical cord stem cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMexico

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesInstituto De Medicina Regenerativa, S.A De Cv

China Registration ClassN/A

Develop Information

Active CompaniesInstituto De Medicina Regenerativa, S.A De Cv

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult

Inactive IndicationsN/A

Other Information

ATC CodeN/A